T- Lymphoblastic lymphoma in adults (original) (raw)
Related papers
Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
Swiss medical weekly, 2013
ASCT autologous stem cell transplantation BEAM conditioning regimen with carmustine, etoposide, cytarabine and melphalan BMI body mass index CBV conditioning regimen with cyclophosphamide, carmustine and etoposide CD34 cluster of differentiation 34 CHOP first-line regimen with prednisone, cyclophosphamide, doxorubicin and vincristine CI confidence interval CLL chronic lymphocytic leukaemia CNS central nervous system CORAL Collaborative Trial in Relapsed Aggressive Lymphoma CR complete remission CRu complete remission unconfirmed Dexa-BEAM salvage regimen with dexamethasone, carmustine, etoposide, cytarabine and melphalan DHAP salvage regimen with dexamethasone, cytarabine and cisplatin DLBCL diffuse large B-cell lymphoma DMSO dimethyl sulfoxide EFS event free survival EPOCH salvage regimen with prednisone, doxorubicin, vincristine, etoposide and cyclophosphamide FDG Fluorodeoxyglucose FL follicular lymphoma G-CSF granulocyte-colony stimulating factor HDC high dose chemotherapy HL Hodgkin's lymphoma HR hazard ratio ICE salvage regimen with ifosfamide, carboplatin and etoposide MCL mantle cell lymphoma NHL Non-Hodgkin's lymphoma OS overall survival PET/CT positron emission tomography/computed tomography PD progressive disease PR partial remission RBC red blood cells SD stable disease TCL T cell lymphoma TRM treatment related mortality Swiss Medical Weekly · PDF of the online version · www.smw.ch References 1 Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-5.
Hematological Oncology, 2019
ASCT at the time of diagnosis; and iii) partial remission (PR) or CR after anthracycline-based first-line treatment. A landmark analysis was performed, with time zero defined as the time at which the assessment after the first-line was carried out. Results: 286 patients were registered. For this analysis, we have only considered 212 patients who were in CR or uncertain CR after first-line chemotherapy. A total of 109 patients underwent ASCT (cases) and 103 did not (controls). The causes for not receiving ASCT were: medical decision (N=84), poor performance status (N=10), patient decision (N=7) and other reasons (N=2). The baseline clinicopathologic characteristics of the patients are listed in table 1. The histologic subtypes were different between groups: angioimmunoblastic T-cell lymphoma and PTCL-NOS were more frequent in the transplant group, whereas anaplastic large cell lymphoma (ALCL), ALK+ was more frequent in the control group. More patients in the transplant group had adverse prognostic factors (table 1). First-line treatment was similar in both groups. With a median follow up of 73.9 months, no significant differences in survival were observed between cases and controls in the overall series. However, after excluding ALCL ALK+ cases, the PFS (65% vs 44% at 5 years, p=0,012) and OS (74% versus 65% at 5 years, p=0,046, figure 1) were significantly better in the patients who underwent ASCT. The PFS advantage in favour of ASCT was independent of IPI or type of first-line chemotherapy in the Cox multivariate analysis (HR 1.62, 95% CI 1.03-2.54, p=0.35). Conclusion: Our results indicate that ASCT in 1st CR improves the survival of patients with PTCL other than ALK+ anaplastic largecell lymphoma. These results should be confirmed in a prospective randomized study. A propensity score matching analysis is planned.
European journal of …, 2007
Angioimmunoblastic T-cell lymphoma (AIL) is a rare Tcell malignancy with characteristic clinical and morphological features (1-3). Although it was originally thought to be a relatively benign disorder and was classified as a low-grade lymphoma, it is currently classified by the WHO as a discrete entity representing around 20% of aggressive T-cell lymphomas. This lymphoma mainly affects elderly people who present an array of characteristic signs and symptoms including disseminated lymphadenopathy, constitutional symptoms, as well as known haematological abnormalities (4). No standard treatment for this aggressive disease has yet been defined, in part due to the relative rarity of the disease. Given the typical relationship of this lymphoma
Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma
Journal of clinical and experimental hematopathology : JCEH, 2016
Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin lymphoma. There are limited reports on allogeneic stem cell transplantation (allo-SCT) in patients with LBL. We retrospectively analyzed the clinical outcomes of 15 adult patients with LBL who received allo-SCT at our institution. The median age at allo-SCT was 29 years (range, 18-42). Disease status at the time of transplantation was complete remission (CR), partial remission (PR), and advanced disease in 4, 4, and 7 patients, respectively. The median follow-up duration of survivors was 25 months (range, 6-106). The probabilities of overall survival (OS) and progression-free survival (PFS) at 2 years after allo-SCT were 37% and 24%, respectively. The respective 2-year OS and PFS rates of the 8 patients with CR or PR at the time of transplantation were 57% and 45%, while those with advanced disease were 14% and 0%. In conclusion, the treatment outcomes of allo-SCT in patients with LBL were unsatisfactory. Although outcome...
Biology of Blood and Marrow Transplantation, 2009
High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) offers a rescue option for T cell lymphoma patients with poor prognosis. However, the effectiveness of HDT/ASCT in patients with various peripheral T cell subtypes, optimal transplant timing, and the prognostic factors that predict better outcomes, have not been identified. We retrospectively investigated the clinical outcomes and prognostic factors for HDT/ASCT in 64 Korean patients with peripheral T cell lymphoma, unspecified (PTCL-U) between March 1995 and February 2007. The median age at transplantation was 44 years (range: 15-63 years). According to the age-adjusted International Prognostic Index (a-IPI) and the prognostic index of PTCL (PIT), 8 patients (12.5%) were in the high-risk group and 16 (26.6%) had the 2-3 PIT factors, respectively. After a median follow-up of 29.7 months, the 3-year overall survival (OS) and progression-free survival (PFS) rates were 53.0% 6 7.5% and 44.3% 6 7.0%, respectively. Univariate analysis showed that poor performance status, high lactate dehydrogenase (LDH) levels, high a-IPI score, high PIT classes, failure to achieve complete response (CR) at transplantation, and nonfrontline transplantation were associated with poor OS. Multivariate analysis showed that failure to achieve CR at transplantation (hazard ratio [HR] 2.23; 95% confidence interval [CI] 1.78-7.93) and 2-3 PIT factors (HR 3.76; 95% CI 1.02-5.42) were independent prognostic factors for OS. Failure to achieve CR at transplantation and high PITare negative predictable factors for survival following HDT/ASCT in patients with PTCL-U.
Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2011
Peripheral T-cell lymphomas (PTCL) are infrequent subtypes of non-Hodgkin's lymphomas. The clinical course is aggressive and the median survival is about 2-3 years. An optimal first-line chemotherapy protocol has not been established and the role of high-dose therapy with autologous stem cell transplantation (ASCT) is still unclear. To analyze the long-term outcome of unselected PTCL patients treated with intensive first-line chemotherapy with high-dose therapy and ASCT. Here we report our experience with 29 patients with PTCL. The histological subtypes were as follows: peripheral T-cell lymphoma, not otherwise specified n=13; anaplastic large cell lymphoma (ALCL) ALK-negative n=5; ALCL ALK-positive n=3; ALCL with an unknown ALK status n=3; angioimmunoblastic lymphoma n=1; hepatosplenic lymphoma n=1; Sézary syndrome n=1; and enteropathy-associated T-cell lymphoma n=2. The median age at diagnosis was 48 years (29-64), most patients had advanced Ann Arbor stages (22 patients, 77%)...